Anuh Pharma Ltd
₹ 87.4
0.19%
18 Sep
2:33 p.m.
About
Incorporated in 1960, Anuh Pharma Ltd is in the business of manufacturing and selling of Bulk drugs and chemicals[1]
Key Points
- Market Cap ₹ 876 Cr.
- Current Price ₹ 87.4
- High / Low ₹ 123 / 74.0
- Stock P/E 19.0
- Book Value ₹ 32.5
- Dividend Yield 1.69 %
- ROCE 17.2 %
- ROE 13.4 %
- Face Value ₹ 5.00
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 21.5%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 266 | 284 | 326 | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 647 | 662 | 710 | |
| 242 | 253 | 289 | 183 | 220 | 291 | 284 | 387 | 439 | 476 | 571 | 600 | 649 | |
| Operating Profit | 24 | 31 | 38 | 23 | 18 | 30 | 23 | 45 | 47 | 52 | 76 | 62 | 61 |
| OPM % | 9% | 11% | 12% | 11% | 8% | 9% | 8% | 10% | 10% | 10% | 12% | 9% | 9% |
| 4 | 5 | 4 | 8 | 7 | 5 | 4 | 11 | 5 | 6 | 12 | 9 | 9 | |
| Interest | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 2 | 3 | 2 | 2 | 2 | 2 | 7 | 15 | 12 | 10 | 9 | 9 | 9 |
| Profit before tax | 25 | 32 | 38 | 28 | 23 | 32 | 19 | 39 | 39 | 47 | 78 | 61 | 60 |
| Tax % | 31% | 31% | 32% | 27% | 29% | 28% | 25% | 26% | 22% | 24% | 23% | 22% | |
| 18 | 22 | 26 | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 60 | 47 | 46 | |
| EPS in Rs | 1.76 | 2.19 | 2.57 | 2.00 | 1.65 | 2.33 | 1.43 | 2.84 | 3.05 | 3.61 | 5.99 | 4.73 | 4.60 |
| Dividend Payout % | 37% | 27% | 24% | 31% | 42% | 29% | 48% | 26% | 29% | 28% | 21% | 16% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 17% |
| 3 Years: | 11% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 26% |
| 3 Years: | 13% |
| TTM: | -20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -3% |
| 3 Years: | 24% |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 15% |
| 3 Years: | 16% |
| Last Year: | 13% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 13 | 13 | 13 | 13 | 13 | 25 | 25 | 25 | 25 | 25 |
| Reserves | 82 | 97 | 107 | 128 | 137 | 152 | 150 | 166 | 189 | 216 | 266 | 301 |
| 0 | 0 | 2 | 0 | 2 | 4 | 45 | 14 | 4 | 1 | 3 | 11 | |
| 77 | 67 | 71 | 48 | 57 | 71 | 119 | 128 | 129 | 163 | 152 | 170 | |
| Total Liabilities | 163 | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 |
| 12 | 9 | 18 | 17 | 17 | 21 | 84 | 71 | 61 | 53 | 49 | 58 | |
| CWIP | 0 | 0 | 0 | 0 | 6 | 34 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 27 | 43 | 43 | 70 | 66 | 39 | 80 | 31 | 43 | 91 | 97 | 106 |
| 124 | 116 | 131 | 101 | 120 | 147 | 163 | 230 | 243 | 261 | 300 | 342 | |
| Total Assets | 163 | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 | 19 | 16 | 26 | 2 | 7 | 49 | -19 | 29 | 54 | 13 | 37 | |
| -5 | -12 | -5 | -20 | 2 | 3 | -77 | 52 | -8 | -43 | 1 | -20 | |
| -8 | -8 | -9 | -4 | -5 | -7 | 22 | -33 | -19 | -12 | -9 | -5 | |
| Net Cash Flow | 2 | -1 | 2 | 2 | -1 | 3 | -5 | 0 | 2 | -2 | 5 | 12 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 102 | 88 | 84 | 100 | 109 | 85 | 96 | 90 | 102 | 118 | 107 | 119 |
| Inventory Days | 33 | 27 | 35 | 72 | 64 | 64 | 98 | 90 | 77 | 66 | 57 | 54 |
| Days Payable | 102 | 79 | 77 | 102 | 105 | 89 | 166 | 133 | 117 | 139 | 105 | 115 |
| Cash Conversion Cycle | 33 | 36 | 42 | 70 | 68 | 61 | 28 | 48 | 62 | 46 | 58 | 59 |
| Working Capital Days | 42 | 43 | 48 | 79 | 80 | 65 | -10 | 57 | 68 | 61 | 69 | 68 |
| ROCE % | 31% | 33% | 35% | 19% | 14% | 19% | 10% | 16% | 18% | 19% | 26% | 17% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Credit Rating
1d - ICRA reaffirmed Anuh Pharma ratings [ICRA]A- (Positive)/A2+ for Rs.90 crore facilities on Sep 15, 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
11 Sep - Newspaper Publication for 100 days Campaign - "Saksham Niveshak."
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Sep - Newspaper Publication regarding notice to shareholders for special window for re-lodgment of transfer request for physical shares.
-
Announcement under Regulation 30 (LODR)-Change in Management
26 Aug - Reappointments: two NEDs; Ritesh & Vivek reappointed JMDs 08-Jan-2026 for five years; cost and secretarial auditors reappointed.
-
Announcement Under Regulation 30 - General Updates
26 Aug - Anuh Pharma reappointed Joint MDs Ritesh and Vivek Shah five-year term from 8 Jan 2026; directors and auditors reappointed.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Aug 2025TranscriptNotesPPT
-
May 2025TranscriptNotesPPT
-
Nov 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021TranscriptNotesPPT
-
Feb 2021Transcript PPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Aug 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
-
Dec 2017TranscriptNotesPPT
-
Feb 2016TranscriptNotesPPT
-
Dec 2015TranscriptNotesPPT
-
Sep 2015TranscriptNotesPPT
-
Aug 2015TranscriptNotesPPT
Business Overview:[1][2]
a) APL is a part of the SK Group and is a leading manufacturer of Macrolides and Anti-TB products in India, besides being a major player in Anti-bacterials, Anti-malarial, Anti-hypertension, and Corticosteroids.
b) It is a medium-sized player in the API/bulk drugs industry, manufacturing products such as erythromycin and its salts, and higher macrolides like azithromycin, roxithromycin, pyrazinamide, and chloramphenicol.
c) The company claims to be the largest producer of erythromycin salts in India and among the top five globally. It is also the largest producer of pyrazinamide in the world.
d) APL has marketing partnerships with 350 customers in over 57 countries, including Europe, Mexico, and South Africa.